AC Immune slumps as Alzheimer's treatment fails in mid-stage study

AC Immune SA

16/06/2022 12:22

** Shares of AC Immune SA  ACIU.O  tumble 26% to $2.13
before the bell after investigational Alzheimer's treatment
fails to meet main goals in a mid-stage study  
    ** Stock among top pct losers across all three major U.S.
stock indexes 
    ** Says crenezumab did not "statistically significantly"
slow or prevent cognitive decline in people with a specific
genetic mutation that causes early-onset of Alzheimer's
 urn:newsml:reuters.com:*:nGNX64TycL
    ** Adds crenezumab's safety profile and favorable numerical
differences observed against placebo in study require further
analyses 
    ** Up to Wednesday's close, ACIU down 42% YTD 

 (Reporting by Bhanvi Satija in Bengaluru)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))